Medtech & Diagnostics
A small medical device company focused on circulating tumor cells was seeking insight into the commercial opportunity and viability of expanding an oncology medical diagnostic currently marketed in the U.S. into key European countries.
ClearView’s extensive experience in oncology diagnostics and specific depth of expertise in global medical device access and reimbursement enabled us to be a strong thought partner for our client.
ClearView conducted a robust assessment of specific market opportunities and reimbursement pathways across the European markets to determine market access viability. From there, we prioritized key markets for potential launch and developed initial go-to-market strategies in each region.
We exhaustively explored the current and future market landscape, specifically evaluating underlying epidemiology and variations by geography. Market research with physicians and payer influencers helped elucidate the value proposition of the test and key reimbursement decisions that may impact uptake. Central drivers and barriers to product adoption were explored to inform how the product would fit into current testing patterns.
ClearView delivered the potential peak EU opportunity for the client with an estimate of time to peak, taking into consideration key risks and uncertainties associated with an EU launch. ClearView also identified key markets to prioritize and deprioritize, along with potential go-to market strategies, and the tradeoffs associated with each approach.